Georgianos Panagiotis I, Agarwal Rajiv
Department of Medicine, Indiana University School of Medicine and Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, IN, United States of America.
PLoS One. 2015 Sep 10;10(9):e0135457. doi: 10.1371/journal.pone.0135457. eCollection 2015.
This study aimed to explore the relative contribution of aortic stiffness and volume in treatment-induced change of left ventricular mass in dialysis. Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril trial compared the effect of lisinopril versus atenolol in reducing left ventricular mass index; 179 patients with echo measurements of aortic pulse wave velocity and left ventricular mass at baseline were included. In unadjusted analysis, overall reductions of 26.24 g/m2 (95% CI: -49.20, -3.29) and 35.67 g/m2 (95% CI: -63.70, -7.64) in left ventricular mass index were noted from baseline to 6 and 12 months respectively. Volume control emerged as an important determinant of regression of left ventricular mass index due to the following reasons: (i) additional control for change in ambulatory systolic blood pressure mitigated the reduction in left ventricular mass index in the statistical model above [6-month visit: -18.6 g/m2 (95% CI: -43.7, 6.5); 12-month visit: -22.1 g/m2 (95% CI: -52.2, 8.0)] (ii) regression of left ventricular hypertrophy was primarily due to reduction in left ventricular chamber and not wall thickness and (iii) adjustment for inferior vena cava diameter (as a proxy for volume) removed the effect of time on left ventricular mass index reduction [6-month visit: -6.6 g/m2 (95% CI: (-41.6, 28.4); 12-month visit: 0.6 g/m2 (95% CI: -39.5, 40.7)]. In contrast, aortic pulse wave velocity was neither a determinant of baseline left ventricular mass index nor predictor of its reduction. Among dialysis patients, ambulatory systolic pressure, a proxy for volume expansion, but not aortic stiffness is more important predictor of reduction in left ventricular mass index. Improving blood pressure control via adequate volume management appears as an effective strategy to improve left ventricular hypertrophy in dialysis.
本研究旨在探讨主动脉僵硬度和容量在透析治疗引起的左心室质量变化中的相对贡献。阿替洛尔或赖诺普利治疗血液透析患者高血压试验比较了赖诺普利与阿替洛尔在降低左心室质量指数方面的效果;纳入了179例在基线时进行了主动脉脉搏波速度和左心室质量超声测量的患者。在未调整分析中,从基线到6个月和12个月时,左心室质量指数分别总体降低了26.24 g/m²(95%CI:-49.20,-3.29)和35.67 g/m²(95%CI:-63.70,-7.64)。容量控制成为左心室质量指数消退的一个重要决定因素,原因如下:(i)对动态收缩压变化进行额外控制减轻了上述统计模型中左心室质量指数的降低[6个月随访时:-18.6 g/m²(95%CI:-43.7,6.5);12个月随访时:-22.1 g/m²(95%CI:-52.2,8.0)](ii)左心室肥厚的消退主要是由于左心室腔减小而非室壁厚度减小,以及(iii)以下腔静脉直径(作为容量的替代指标)进行调整消除了时间对左心室质量指数降低的影响[6个月随访时:-6.6 g/m²(95%CI:(-41.6,28.4);12个月随访时:0.6 g/m²(95%CI:-39.5,40.7)]。相比之下,主动脉脉搏波速度既不是基线左心室质量指数的决定因素,也不是其降低的预测指标。在透析患者中,作为容量扩张替代指标的动态收缩压,而非主动脉僵硬度,是左心室质量指数降低的更重要预测指标。通过适当的容量管理改善血压控制似乎是改善透析患者左心室肥厚的有效策略。